Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 16.375 16.00 16.75 16.375 16.375 16.375 113,249 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.4 -0.9 - 26

SkinBioTherapeutics PLC Appointment of Senior Medical Advisor

08/09/2020 7:19am

UK Regulatory (RNS & others)


Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart


From Aug 2020 to Nov 2020

Click Here for more Skinbiotherapeutics Charts.

TIDMSBTX

RNS Number : 3294Y

SkinBioTherapeutics PLC

08 September 2020

8 September 2020

SkinBioTherapeutics plc

Appointment of Senior Medical Advisor

SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, announces the appointment of Dr Jonathan Sheffield as a Senior Medical Advisor with immediate effect.

Jonathan formerly served as the CEO of the National Institute for Health Research (NIHR), Clinical Research Network since 2010. The Clinical Research Network delivers clinical research studies throughout the NHS in England covering primary, secondary and tertiary care. In 2018-19, the Network recruited over 902,000 patients into over 5,250 studies across the NHS.

Jonathan qualified as a doctor in 1981 and trained as a Histopathologist. He has subsequently held multiple senior medical management posts in the NHS at local, regional and national levels and was awarded an OBE for service to the NHS in 2009. Jonathan was elected an Honorary Fellow of the Royal College of Physicians' Faculty of Pharmaceutical Medicine in 2011 for his contribution in the area of clinical research delivery.

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"Jonathan will bring to SkinBioTherapeutics broad clinical knowledge accumulated over his career. Having served as CEO of the Clinical Research Network for 10 years, he has the expertise and extensive network in clinical research that will be of critical importance to the Company as we progress our product development programmes."

Dr Jonathan Sheffield, Senior Medical Advisor at SkinBioTherapeutics, said:

"Throughout my career I have been passionate about innovative, ground-breaking science, and how medical knowledge can be advanced through clinical research to improve lives. SkinBioTherapeutics' technology is one that is grounded in compelling science and has the potential to make a material difference for patients in several areas through its multiple programmes. I look forward to getting to know the team and the technology over the coming months."

-Ends-

For more information please contact:

 
 SkinBioTherapeutics plc                            Tel: +44 (0) 161 
                                                     468 2760 
 Stuart Ashman, CEO 
  Doug Quinn, CFO 
 
 Cenkos Securities plc (Nominated Adviser &         Tel: +44 (0)20 7397 
  Broker)                                            8900 
 Giles Balleny, Max Gould (Corporate Finance) 
  Michael Johnson (Sales) 
 
 Instinctif Partners                                Tel: +44 (0) 20 7457 
                                                     2020 
 Melanie Toyne-Sewell / Phillip Marriage / Nathan    SkinBio@instinctif.com 
  Billis 
 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotherapeutics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGLGDCRBGDGGI

(END) Dow Jones Newswires

September 08, 2020 02:19 ET (06:19 GMT)

1 Year Skinbiotherapeutics Chart

1 Year Skinbiotherapeutics Chart

1 Month Skinbiotherapeutics Chart

1 Month Skinbiotherapeutics Chart
ADVFN Advertorial
Your Recent History
LSE
SBTX
Skinbiothe..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201125 09:38:08